These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34396556)

  • 1. Pharmacologic Similarities and Differences Among Hallucinogens.
    Waters K
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A; Moning OD; Hoener MC; Liechti ME
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.
    Winter JC
    Psychopharmacology (Berl); 2009 Apr; 203(2):251-63. PubMed ID: 18979087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
    Koerner J; Appel JB
    Psychopharmacology (Berl); 1982; 76(2):130-5. PubMed ID: 6805022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ.
    Haefely W
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 281(2):145-65. PubMed ID: 4361056
    [No Abstract]   [Full Text] [Related]  

  • 10. The possible role of tryptamine in brain function and its relationship to the actions of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Mt Sinai J Med; 1974; 41(2):276-82. PubMed ID: 4544624
    [No Abstract]   [Full Text] [Related]  

  • 11. The hallucinogenic world of tryptamines: an updated review.
    Araújo AM; Carvalho F; Bastos Mde L; Guedes de Pinho P; Carvalho M
    Arch Toxicol; 2015 Aug; 89(8):1151-73. PubMed ID: 25877327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines.
    Cerletti A; Taeschler M; Weidmann H
    Adv Pharmacol (1962); 1968; 6(Pt B):233-46. PubMed ID: 5658327
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
    Halberstadt AL
    Behav Brain Res; 2015 Jan; 277():99-120. PubMed ID: 25036425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
    Fantegrossi WE; Reissig CJ; Katz EB; Yarosh HL; Rice KC; Winter JC
    Pharmacol Biochem Behav; 2008 Jan; 88(3):358-65. PubMed ID: 17905422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
    Holze F; Singh N; Liechti ME; D'Souza DC
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic therapy in depression and substance use disorders.
    Korkmaz ND; Cikrikcili U; Akan M; Yucesan E
    Eur J Neurosci; 2024 Jul; 60(2):4063-4077. PubMed ID: 38773750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 20. Serotonin accumulation after monoamine oxidase inhibition. Effects of decreased impulse flow and of some anti-depressants and hallucinogens.
    Meek JL; Fuxe K
    Biochem Pharmacol; 1971 Mar; 20(3):693-706. PubMed ID: 5150164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.